Clinical Trial Update: A Phase I Study of FCN-411 in Advanced Non-small Cell Lung Cancer Chinese Patients With EGFR Positive Mutation [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II clinical trial update for FCN-411 in advanced non-small cell lung cancer with EGFR mutation in Chinese patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• FCN-411

Snippet

Sponsor: Ahon Pharmaceutical Co., Ltd. | Conditions: Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN